Abstract:Stress-induced promoter-associated and antisense lncRNAs (si-paancRNAs) originate from a reservoir of oxidative stress (OS)-specific promoters via RNAPII pausing-mediated divergent antisense transcription. Several studies have shown that the KDM7A divergent transcript gene (KDM7A-DT), which encodes a si-paancRNA, is overexpressed in some cancer types. However, the mechanisms of this overexpression and its corresponding roles in oncogenesis and cancer progression are poorly understood. We found that KDM7A-DT expression is correlated with highly aggressive cancer types and specific inherently determined subtypes (such as ductal invasive breast carcinoma (BRCA) basal subtype). Its regulation is determined by missense TP53 mutations in a subtype-specific context. KDM7A-DT transcribes several intermediate-sized ncRNAs and a full-length transcript, exhibiting distinct expression and localization patterns. Overexpression of KDM7A-DT upregulates TP53 protein expression and H2AX phosphorylation in nonmalignant fibroblasts, while in semi-transformed fibroblasts, OS superinduces KDM7A-DT expression in a TP53-dependent manner. KDM7A-DT knockdown and gene expression profiling in TP53-missense mutated luminal A BRCA variant, where it is abundantly expressed, indicate its significant role in cancer pathways. Endogenous over-expression of KDM7A-DT inhibits DNA damage response/repair (DDR/R) via the TP53BP1-mediated pathway, reducing apoptosis and promoting G2/M checkpoint arrest. Higher KDM7A-DT expression in BRCA is associated with KDM7A-DT locus gain/amplification, higher histologic grade, aneuploidy, hypoxia, immune modulation scores, and activation of the c-myc pathway. Higher KDM7A-DT expression is associated with relatively poor survival outcomes in patients with luminal A or Basal subtypes. In contrast, it is associated with favorable outcomes in patients with HER2+ER- or luminal B subtypes. KDM7A-DT levels are coregulated with critical transcripts and proteins aberrantly expressed in BRCA, including those involved in DNA repair via non-homologous end joining and epithelial-to-mesenchymal transition pathway. In summary, KDM7A-DT and its si-lncRNA exhibit several intrinsic biological and clinical characteristics that suggest important roles in invasive BRCA and its subtypes. KDM7A-DT-defined mRNA and protein subnetworks offer resources for identifying clinically relevant RNA-based signatures and prospective targets for therapeutic intervention.

DPM2 serve as novel oncogene and prognostic marker transactivated by ESR1 in breast cancer

PBRM1 Presents a Potential Prognostic Marker and Therapeutic Target in Duodenal Papillary Carcinoma

Oncogenic Functions of Protein Kinase D2 and D3 in Regulating Multiple Cancer-Related Pathways in Breast Cancer

PDSS2 Promotes Epithelial-Mesenchymal Transition and Angiogenesis in Breast Cancer Cells by Activating the NF-KB Pathway

PDP1 promotes the progression of breast cancer through STAT3 pathway

GSDMS Are Potential Therapeutic Targets and Prognostic Biomarkers in Breast Cancer

Identification of MDM2 As a Prognostic and Immunotherapeutic Biomarker in a Comprehensive Pan-Cancer Analysis: A Promising Target for Breast Cancer, Bladder Cancer and Ovarian Cancer Immunotherapy

PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation.

Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

Transcriptomic Profiling Identifies DCBLD2 As a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.

Tumor Suppressor Drd2 Facilitates M1 Macrophages And Restricts Nf-Kappa B Signaling To Trigger Pyroptosis In Breast Cancer

DPM1 Expression As a Potential Prognostic Tumor Marker in Hepatocellular Carcinoma.

Comprehensive analysis of PDE2A: a novel biomarker for prognostic value and immunotherapeutic potential in human cancers

PD-L2 Expression in Breast Cancer Promotes Tumor Development and Progression

Down-regulation of ESRP2 inhibits breast cancer cell proliferation via inhibiting cyclinD1

DACT2 Silencing by Promoter CpG Methylation Disrupts Its Regulation of Epithelial-to-mesenchymal Transition and Cytoskeleton Reorganization in Breast Cancer Cells.

Pan-cancer Analysis of Oncogenic Role of Programmed Cell Death 2 Like (PDCD2L) and Validation in Colorectal Cancer

KDM7A-DT induces genotoxic stress, tumorigenesis, and progression of p53 missense mutation-associated invasive breast cancer

MDM2 and PSMA Play Inhibitory Roles in Metastatic Breast Cancer Cells Through Regulation of Matrix Metalloproteinases.

SKP2 Promotes Breast Cancer Tumorigenesis and Radiation Tolerance Through PDCD4 Ubiquitination.

Increased Expression of TMED2 is an Unfavorable Prognostic Factor in Patients with Breast Cancer